Delivery Order SPE2DR25D3301-SPE2DR26F18VG
Award Date 12/2/25
Potential Completion Date 12/3/25
Potential Value $10K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $37,755.40 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 8, 2025, with a completion date of December 9, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults aged 18 years and...
- The Defense Logistics Agency awarded a $2,447.64 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years and older, and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,039.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on December 3, 2025, with completion scheduled for December 4, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 years and older. This delivery order was competitively awarded without set-aside designation under a firm fixed price contract structure, with performance at the contractor's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,605.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with ultimate completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes. The contract is a firm fixed price delivery order with no set-aside designation, executed on May 27, 2025, with an ultimate completion date of May 28, 2025. Performance will occur at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing the type...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $7,333.24 on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years of age and older, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $105,310.00 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed price delivery order was awarded without set-aside designation through competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of June 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order was placed to support federal medical procurement needs, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $40,921.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order, placed without set-aside designation, represents a competitive award under the company's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....